Septerna FY2025 EPS Estimate Reduced by HC Wainwright

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Septerna, Inc. (NASDAQ:SEPN - Free Report) - Stock analysts at HC Wainwright decreased their FY2025 earnings per share estimates for Septerna in a report released on Monday, August 18th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of $0.99 for the year, down from their previous forecast of $1.01. HC Wainwright has a "Buy" rating and a $26.00 price target on the stock. The consensus estimate for Septerna's current full-year earnings is ($7.11) per share.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Septerna from a "hold" rating to a "sell" rating in a report on Saturday, August 16th. Cantor Fitzgerald boosted their price objective on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Finally, Wells Fargo & Company boosted their price objective on Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Stock Performance

Shares of SEPN stock traded up $0.29 during trading hours on Tuesday, hitting $11.99. 362,953 shares of the company were exchanged, compared to its average volume of 676,196. The firm has a market cap of $534.51 million and a P/E ratio of -1.19. Septerna has a fifty-two week low of $4.17 and a fifty-two week high of $28.99. The company has a 50 day simple moving average of $11.61 and a two-hundred day simple moving average of $9.07.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC purchased a new position in Septerna during the fourth quarter valued at $25,000. JPMorgan Chase & Co. lifted its position in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter. Legal & General Group Plc purchased a new position in Septerna during the fourth quarter valued at $42,000. Summit Investment Advisors Inc. purchased a new position in Septerna during the fourth quarter valued at $45,000. Finally, BNP Paribas Financial Markets purchased a new position in Septerna during the fourth quarter valued at $52,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.